Publicly insured youth of minority and lower SES backgrounds are disproportionately impacted by the burden of T2D. The role of CGM use in this population is understudied, and patient-reported outcomes are important to assess while examining feasibility and acceptability of CGM adoption. This study assessed PROs during a feasibility study of CGM use. Youth were provided or prescribed flash CGM using established clinic workflows; PROs were collected from youth and parents at baseline, 3 and 12-month visits using age-appropriate measures (PAID-diabetes distress; PedsQL-health-related quality of life; PROMIS Global Health; DTA-diabetes technology attitudes). Baseline and 3-month data are presented. Participants at baseline included 30 youth with T2D (M age 15.1 years; 53% female; 90% Hispanic; 60% Spanish-speaking; 87% using insulin; M HbA1C 10.2%); 19 parents completed PROs at baseline. Parents and youth had moderate-to-positive attitudes about diabetes technology. Youth endorsed fair levels of global health; and youth and parents endorsed fair general and diabetes-related health-related quality of life. These PROs point to potential areas for future study to understand sources of lower self-reported health and quality of life, and to develop tailored interventions to address PROs while supporting CGM use in publicly-insured youth with T2D.
M.L.Tanenbaum: None. S.Hanes: None. K.K.Hood: Consultant; Cecelia Health. D.M.Maahs: Advisory Panel; Medtronic, LifeScan Diabetes Institute, MannKind Corporation, Consultant; Abbott, Research Support; Dexcom, Inc. S.Shah: Research Support; Boehringer-Ingelheim, Takeda Pharmaceutical Co., Ltd.